MedPath

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Completed
Conditions
Peripheral Vascular Diseases
Atherosclerosis
Hyperlipidemias
Diabetes Mellitus
Coronary Heart Disease
Carotid Stenosis
Registration Number
NCT00536796
Lead Sponsor
AstraZeneca
Brief Summary

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1096
Inclusion Criteria
  • Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy
Read More
Exclusion Criteria
  • Patients who do not receive cholesterol-lowering therapy
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cholesterol levelsAfter 4 weeks

Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇦🇹

Rohrbach, Upper Austria, Austria

© Copyright 2025. All Rights Reserved by MedPath